A method of performing ultrasound motion tracking of a urethra or other pelvic floor structure includes obtaining a plurality of ultrasound images of a urethra or pelvic floor structure, identifying a reference element in the plurality of ultrasound images, and determining one or more regions of interest in the first ultrasound image including a portion of the urethra. A processor determines first and second positions, relative to the reference element, of the regions of interest in the plurality of ultrasound images. The processor further determines a change in position of the urethra from the first and second positions of the regions of interest. The processor may further determine orientations, opening, closing, or other movement of the urethra from the first and second positions of the regions of interest.
The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
4.
STRAIN-BASED POLARIZATION AND CHARGE CARRIER GENERATION IN WURTZITE SEMICONDUCTOR DEVICES
A device includes a substrate including a template layer, the template layer including a polar material, and a heterostructure supported by the substrate and in contact with the polar material. The heterostructure includes a barrier layer and a channel layer. The barrier layer includes a first wurtzite semiconductor material. The channel layer includes a second wurtzite semiconductor material. The first and second wurtzite semiconductor materials have different in-plane lattice constants such that the channel layer is under lateral strain.
A nasal photobiomodulation device including an elongate body having an outer surface disposed between a proximal end and a distal end. The photobiomodulation device further includes a first lumen and a second lumen disposed along at least a portion of the length of the elongate body. The first and second lumens have a first end and a second end. The first ends are disposed adjacent the proximal end of the elongate body and the second ends open through the outer surface of the elongate body. The second end of the second lumen disposed adjacent the second end of the first lumen.
In an implementation, a nasopharyngeal airway device (100) includes an elongate body (102) having a distal end (104) and a proximal end (106). The elongate body defines a channel (108) extending along the elongate body. The elongate body has a wall (110) having a first portion (112) and a second portion (114). The first portion is thicker than the second portion to deter the elongate body from inwardly collapsing.
Provided herein are systems and methods for decreasing blood vessel density, removing blood vessels or capillaries, and/or treating a cutaneous vascular malformation (e.g., port-wine stain) in a subject. The methods comprise applying a laser pulse(s) spatiotemporally synchronized with an ultrasound burst(s) to at least a portion of target area (e.g., an affected skin surface or tissue up to 3 mm from the skin surface).
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
A61F 9/008 - Methods or devices for eye surgery using laser
A61B 18/26 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor for producing a shock wave, e.g. laser lithotripsy
9.
Scalable Graph-Based Approach To Accelerating Recommendation Model Inference
The high memory bandwidth demand of sparse embedding layers continues to be a critical challenge in scaling the performance of recommendation models. A lightweight and scalable graph-based algorithm-system co-design framework is proposed to significantly improve the embedding layer performance of recommendation models. This framework includes a novel item co-occurrence graph that scalably records item co-occurrences. Additionally, a new system-aware graph clustering algorithm is presented to find frequently accessed item combinations of arbitrary lengths to compute and memorize their partial sums. High-frequency partial sums are stored in a software-managed cache space to reduce memory traffic and improve the throughput of computing sparse features.
Provided herein are compositions and methods for modulating gut microbiomes to treat or prevent diseases. For example, provided herein are microorganisms or components thereof (e.g., proteins involved in associating dietary fibers, such as resistant starch, with beneficial gut microorganisms) that find use treating diseases having an inflammatory component, such as Graft versus Host Disease and cancer. Prebiotic, probiotic, and synbiotic compositions are also provided. In some embodiments, the bacteria are those that naturally express pili that attach to RS granules. In other embodiments, the bacterial are engineered to express or present pili or pilus proteins (e.g., tip pilin) that attach to RS granules.
A subwavelength metalens includes a layer of silicon nitride having a refractive index greater than 2.0. The refractive index may be tailored to be within a range from 2.0 to 3.2 based on parameters of a vapor deposition process in which reactive gases are introduced into the deposition chamber in a ratio that forms silicon nitride in which the ratio of silicon to nitrogen is greater than that of Si3N4. These high refractive index materials enable reduction of a pitch size within which phase shifters of the lens are formed without increasing the thickness of the material relative to conventional metalens materials such as TiO2 or GaN.
The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
13.
TAURINE AND/OR A PRODRUG THEREOF FOR THE TREATMENT OF CYSTINOSIS
Provided herein are methods for treating, preventing and/or ameliorating. cystinosis in a subject comprising administering an effective amount of taurine and/or a prodrug thereof to the subject.
Systems and methods for fabricating an adjustable width kirigami structure for tissue fabrication and testing are disclosed. An example method includes forming, by a laser cutting device, at least two kirigami structure substrates that include a plurality of bendable pillars. The example method further includes bending each of the plurality of bendable pillars to an erected position for each of the at least two kirigami structure substrates. The example method further includes layering a first kirigami structure substrate of the at least two kirigami structure substrates over a second kirigami structure substrate of the at least two kirigami structure substrates, such that the first kirigami structure substrate is antiparallel relative to the second kirigami structure substrate, to generate an adjustable width kirigami structure.
Provided herein are methods of treatment, compositions, systems and kits using polymer particles as restraints of neutrophil function. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be implicated. In some embodiments, polymer particles are useful for diagnosing neutrophil related diseases or conditions.
Huazhong University of Science and Technology (China)
The Regents of the University of Michigan (USA)
Inventor
Liu, Zeyang
Zhang, Cheng
Guo, Lingjie Jay
Gao, Hao
Abstract
Disclosed is a type planar-waveguide-based multi-channel crosstalk-free metasurface holographic devices, including a glass planar waveguide and a metasurface above the glass planar waveguide; light propagates inside the planar waveguide in the form of total internal reflections and illuminates the metasurface; the metasurface is capable of selectively projecting multiple crosstalk-free and independent holographic images according to different combinations of circular polarization state and azimuth angle of the total internal reflection incident light inside the waveguide. The device utilizes two properties of incident light, namely the state of polarization and the angle of incidence, and can selectively project multiple independent crosstalk-free holographic images according to the state of polarization and the propagation azimuthal angle of the total internal reflection light in the waveguide. In addition, the device has broadband operational property, such that the projected target images can have different colors.
G02B 6/35 - Optical coupling means having switching means
F21V 8/00 - Use of light guides, e.g. fibre optic devices, in lighting devices or systems
G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
G02B 6/38 - Mechanical coupling means having fibre to fibre mating means
G03H 1/00 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto
17.
OUT OF PLANE INTER-STAGE CONNECTION IN FLEXURE MECHANISMS
A multitude of flexure mechanism designs are set forth herein that furnish enhanced stiffness properties. The flexure mechanism designs can have various stages including ground stages, motion stages, flexure stages, and reinforcement stages, among other possible stages depending on the construction of the flexure mechanism designs. It has been determined that stages constituting twin stages can be connected via one or more inter-stage connections.
A water splitting system includes a hydrogen production chamber including a hydrogen production port, an oxygen production chamber including an oxygen collection port, an ion exchange membrane coupling the hydrogen production chamber and the oxygen production chamber, and a photocatalytic structure including a first catalytic portion disposed in the hydrogen production chamber and a second catalytic portion disposed in the oxygen production chamber. The first catalytic portion is configured for production of hydrogen via the hydrogen production port. The second catalytic portion is configured for production of oxygen via the oxygen production port.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 9/50 - Cells or assemblies of cells comprising photoelectrodesAssemblies of constructional parts thereof
A device includes a substrate, first and second electrodes supported by the substrate, and a heterostructure supported by the substrate. The heterostructure includes first and second dielectric layers and a ferroelectric III-nitride alloy layer disposed between the first and second dielectric layers, the ferroelectric III-nitride alloy layer including a Group IIIB element. The ferroelectric III-nitride alloy layer is electrically spaced from the first and second electrodes by the first and second dielectric layers, respectively.
A fiber optic distributed sensing system and method. The fiber optic distributed sensing system includes: an optical fiber extending through an underwater gas field; an interrogator connected to the optical fiber so that light transmitted through the optical fiber is capable of being sensed by the interrogator; and a computer system configured to obtain sensor data captured by the interrogator and determine an amount or a characteristic of gas within the underwater gas field based on the sensor data. The method includes: capturing sensor data using a fiber optic distributed sensor extending through an acoustic field; performing a wavelet transform on the sensor data in order to obtain spatiotemporal data; and matching the spatiotemporal data to an event template of a predetermined set of event templates in order to identify a spatiotemporal event.
G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
G01H 9/00 - Measuring mechanical vibrations or ultrasonic, sonic or infrasonic waves by using radiation-sensitive means, e.g. optical means
G01D 5/353 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using optical means, i.e. using infrared, visible or ultraviolet light with attenuation or whole or partial obturation of beams of light the beams of light being detected by photocells influencing the transmission properties of an optical fibre
21.
SMALL MOLECULE MODULATORS OF SIRT5 AND USES THEREOF
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of carbothioamide (and structurally related) small-molecule compounds which function as inhibitors of SIRT5, and their use as therapeutics for the treatment of diseases associated with posttranslational modification functions (e.g., diseases associated with SIRT5 activity) (e.g., cancer (e.g., melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), ovarian cancer, colorectal cancer (CRC), acute myeloid leukemia (AML), Ewing's sarcoma, brain cancer, pancreatic cancer, renal cancer, breast cancer, prostate cancer, lung cancer, leukemia and lymphoma), diabetes, autoimmune diseases, inflammatory diseases, fibrotic diseases, cardiovascular diseases, and neurodegenerative diseases).
A multitude of flexure mechanism designs are set forth herein that furnish enhanced stiffness properties. The flexure mechanism designs can have various stages including ground stages, motion stages, flexure stages, and reinforcement stages, among other possible stages depending on the construction of the flexure mechanism designs. It has been determined that stages constituting sister stages can be connected via one or more in-plane inter-stage connections.
A multitude of flexure mechanism designs are set forth herein that furnish enhanced stiffness properties. The flexure mechanism designs can have various stages including ground stages, motion stages, flexure stages, and reinforcement stages, among other possible stages depending on the construction of the flexure mechanism designs. It has been determined that stages constituting sister stages can be connected via one or more in-plane inter-stage connections.
A method of manufacturing and assembling a sandwich flexure mechanism assembly is set forth herein. The method involves manufacture of a monolithic sandwich flexure module having a multitude of out of plane rigid inter-stage connections between at least some sets of twin stages of the monolithic sandwich flexure module. The method further involves assembling an interconnect subassembly to intermediate bodies of the monolithic sandwich flexure module. The interconnect subassembly furnishing in-plane rigid inter-stage connections between pairs of the intermediate bodies that constitute sister stages of the monolithic sandwich flexure module. The method can further involve assembling a motion body, actuators, and displacement sensors at the monolithic sandwich flexure module.
A multitude of flexure mechanism designs are set forth herein that furnish enhanced stiffness properties. The flexure mechanism designs can have various stages including ground stages, motion stages, flexure stages, and reinforcement stages, among other possible stages depending on the construction of the flexure mechanism designs. It has been determined that stages constituting twin stages can be connected via one or more inter-stage connections.
A method of manufacturing and assembling a sandwich flexure mechanism assembly is set forth herein. The method involves manufacture of a monolithic sandwich flexure module having a multitude of out of plane rigid inter-stage connections between at least some sets of twin stages of the monolithic sandwich flexure module. The method further involves assembling an interconnect subassembly to intermediate bodies of the monolithic sandwich flexure module. The interconnect subassembly furnishing in-plane rigid inter-stage connections between pairs of the intermediate bodies that constitute sister stages of the monolithic sandwich flexure module. The method can further involve assembling a motion body, actuators, and displacement sensors at the monolithic sandwich flexure module.
G02B 7/18 - Mountings, adjusting means, or light-tight connections, for optical elements for prismsMountings, adjusting means, or light-tight connections, for optical elements for mirrors
27.
DUAL FUNCTIONING IMMUNE MODULATING COMPOUNDS, FORMULATIONS, AND USES THEREOF
The present disclosure provides dual functioning compounds, compositions, formulations, and methods for inducing or modulating an immune or inflammatory response and treating diseases or disorders (e.g., cancer, autoimmune diseases, inflammatory diseases, and infectious diseases) with the compounds or compositions thereof. In particular disclosed herein are dual functioning compounds comprising a stimulator of interferon (IFN) genes (STING) agonist moiety and a second active moiety selected from an indoleamine 2,3-dioxygenase (IDO) inhibitor and phosphatidylinositol 3-kinase (PI3K) inhibitor, and compositions and formulations thereof.
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure provides compounds, compositions, formulations, and methods for delivery of active agents (e.g., nucleic acid). In particular, the present disclosure provides modified lipids (e.g., lipids conjugated with 1-methyl-D-tryptophan) for use in delivery of active agents and compositions and vaccines thereof.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
UNIVERSIDADE ESTADUAL DE MATO GROSSO DO SUL (Brazil)
Inventor
Rand, Stephen
Reis Silva, Junior
Abstract
An illumination source is configured to illuminate a medium, having a chromium-based dopant, with light at a wavelength selected based on an emission band of a selected absorption band of the medium. The selected absorption and emission bands being associated with an electric-dipole-allowed transition of the medium. Upon illumination by the light the medium is cooled.
A method of fabricating a heterostructure includes providing a substrate, the substrate including silicon carbide, the substrate having a carbon (C)-face, forming a III-nitride-based buffer layer of the heterostructure, the III-nitride-based buffer layer being in contact with the C-face of the substrate, and implementing a molecular beam epitaxy (MBE) procedure to grow a III-nitride-based layer such that the III-nitride-based layer is supported by the III-nitride-based buffer layer. The molecular beam epitaxy (MBE) procedure is implemented under nitrogen (N)-rich conditions
Methods of making an integrated electrode-separator component for a lithium-sulfur electrochemical cell are provided. A liquid dispersion comprising aramid nanofibers (ANF) is sprayed onto an active material layer comprising at least one electroactive material to form a sprayed layer that defines an integrated electrode-separator component having an interfacial resistance between the sprayed layer and the active material layer of less than or equal to about 10 Ω·cm2. An electrode-separator component and lithium-sulfur electrochemical cell are also provided.
H01M 50/489 - Separators, membranes, diaphragms or spacing elements inside the cells, characterised by their physical properties, e.g. swelling degree, hydrophilicity or shut down properties
The technology described herein provides methods and systems related to feature processing of tissues and/or cells (e.g., to provide histological information describing the tissues and/or cells). In particular, methods and systems are described that classify, segment, and/or analyze target classes in images of (e.g., representing) tissues and/or cells. The technology finds use in validating the safety and quality of the objects. Aspects of the technology use artificial intelligence machine learning to classify, segment, and/or analyze ovarian follicles from images of human donor ovarian tissue.
G01N 33/483 - Physical analysis of biological material
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
33.
SIGMA-2 RECEPTOR (TMEM97) LIGANDS FOR OCULAR HEALING
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
Inventor
Ondrus, Alison E.
Cologna, Stephanie M.
Son, Kyung No
Aakalu, Vinay
Abstract
Provided herein are methods, compositions, and kits to promote ocular healing. In particular, provided herein are reagents and methodologies to promote ocular healing comprising a sigma-2 receptor (TMEM97) ligand.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A system for determining a weight for a rule that governs a manner of a performance of a change of a movement of an automated vehicle can determine the weight from responses, from a human subject, to questions about preferences about the manner of the performance. The questions can be selected, using a greedy technique, from a question set. The weight can be applied to the rule to incorporate the preference of the human subject about the manner of the performance. The preference can be with respect to one or more of: (1) a degree of comfort of the human subject during the performance, (2) a degree of vehicle performance of the automated vehicle during the performance, or (3) the like. Such a rule can increase a likelihood that a human driver (i.e., the human subject) will accept having the automated vehicle operated under control of an automated driving system.
Methods of additive manufacturing are provided including depositing a printable cementitious composition in a non-planar toolpath by passing the printable cementitious composition through a printhead of a robotic additive manufacturing device to deposit the cementitious composition onto a target. The depositing process forms at least one layer of an additively manufactured cementitious structure. In certain aspects, the additively manufactured structure is a topology optimized (TO) structure having a complex geometry. The methods may use geometrically informed techniques, such as a geometrically informed non-planar (GINP) toolpath, while the depositing further comprises employing a geometrically informed variable (GIV) material deposition method that (i) regulates a flow rate of material passing through the printhead during the depositing; (ii) regulates a speed of the print head; or (iii) both (i) and (ii). The robotic additive manufacturing device may be an automated three-dimensional printer at least partially controlled by a computer numerical control (CNC) system.
B28B 1/00 - Producing shaped articles from the material
B28B 23/02 - Arrangements specially adapted for the production of shaped articles with elements wholly or partly embedded in the moulding material wherein the elements are reinforcing members
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing courses in research methods, statistics, data analysis, and social methodology that encourage the use of data in teaching and encouragement of publications and guidance that address issues related to data stewardship, digital curation, and data science. Providing a data archive for data access, curation, and methods of analysis of digital research data in the social sciences, including specialized collections of data in demography, aging, criminal justice, substance abuse, and other fields
Provided herein are compositions, methods, systems and kits for generation of protein nanocompartment encapsulins for concurrent RNA and protein encapsulation within bacterial cells. In particular, provided herein are reagents and methodologies for generation and use of encapsulins providing simultaneous in vivo packaging of specific RNAs and specific proteins of interest.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 2-hydroxybenzoic acid structure which function as sirtuin (e.g., SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7) inhibitors and/or degraders which function as effective therapeutic agents for treating, ameliorating, and preventing disorders associated with sirtuin activity (e.g., melanoma, Ewing sarcoma, malignant peripheral nerve sheath tumor, non-small cell lung cancer). In addition, this invention also relates to a new class of proteolysis-targeting chimeras (PROTACs) (as defined herein) which function as sirtuin inhibitors and/or degraders within cancer and/or immune cells. Pharmaceutical compositions comprising said compounds are also within the scope of the present invention.
C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07D 277/48 - Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
The present disclosure provides STING agonists, and compositions, formulations, and methods for treating diseases or disorders (e.g., cancer, inflammatory diseases, autoimmune diseases, and infectious diseases) with the STING agonists or compositions thereof.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
C07D 333/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A tandem photovoltaic (PV) device comprises a substrate, a reflector layer on one side of the substrate, a first PV sub-cell in optical communication with the reflector layer configured to absorb visible light; and a second PV sub-cell above the first PV sub-cell configured to absorb NIR light.
H10K 30/57 - Photovoltaic [PV] devices comprising multiple junctions, e.g. tandem PV cells
H10K 30/35 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains comprising inorganic nanostructures, e.g. CdSe nanoparticles
H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
H10K 71/16 - Deposition of organic active material using physical vapour deposition [PVD], e.g. vacuum deposition or sputtering
A lung cancer chemoprevention drug delivery platform comprises a Janus nanoparticle comprising at least two chemopreventive agents for preventing/minimizing lung cancer or preventing recurrence of treated lung cancer. Further, an aerosolized composition is provided that comprises (a) at least one Janus nanoparticle configured to be aerosolized; (b) a bioactive protein inhibitor; (c)a modulator of at least one proinflammatory mediator; (d) an immune checkpoint inhibitor; and (e) short interfering sequence of double stranded RNA (siRNA) to modify proteins aberrantly upregulated in premalignant lung lesions. In another variation, methods for generating a lung cancer chemoprevention drug delivery platform for inhalation by a subject diagnosed with premalignant lung lesion is provided, where the drug delivery platform comprising: (a) a Janus nanoparticle, (b) a bioactive protein inhibitor; (c) a modulator of at least one proinflammatory mediator; (d) an immune checkpoint inhibitor; and (e) siRNA to modify proteins aberrantly upregulated in premalignant lung lesions.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
An optically active nanocomposite material is provided that may have a textured substrate and a multilayer optic stack with a plurality of layers comprising nanoplatelets. The nanoplatelets may be achiral and formed of a material such as transition metal chalcogenides, Mxenes, or nanocarbons. The optically active nanocomposite material displays both linear birefringence (LB) and linear dichroism (LD) and optional circular dichroism (CD). The nanocomposite may have an optical asymmetry g-factor of greater than or equal to about 1. Further, the nanocomposite is thermally stable, for example, to a temperature of greater than or equal to about 250° C. Different methods of fabricating such nanocomposites using layer-by-layer (LBL) processes are also provided.
B32B 27/18 - Layered products essentially comprising synthetic resin characterised by the use of special additives
B32B 3/28 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layerLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a layer with cavities or internal voids characterised by a layer comprising a deformed thin sheet, e.g. corrugated, crumpled
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
B82Y 40/00 - Manufacture or treatment of nanostructures
43.
METHOD FOR TREATING AUTOPHAGY DEPENDENT CANCER WITH A PIKFYVE DEGRADER
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (China)
Inventor
Wang, Zhen
Li, Chengun
Ding, Ke
Cheng, Caleb
Qiao, Yuanyuan
Lyssiotis, Costas
Chinnaiyan, Arul M.
Abstract
Provided herein are methods for treating autophagy dependent cancers. In particular, provided herein are methods for treating neuroendocrine prostate cancer (NEPC), pancreatic ductal adenocarcinoma (PDAC), pancreatic neuroendocrine tumors (PNETs), and pancreatic neuroendocrine carcinomas (NECs) comprising administering a therapeutic agent, e.g., PIK5-12D or LCG-33, that inhibits PIKfyve.
A computer system includes memory hardware configured to store computer-executable instructions, and a network of multiple tensor networks, each tensor network including multiple nodes. The computer system includes processor hardware configured to execute the computer-executable instructions to transmit a ping request from a first tensor network of the multiple tensor networks to a second tensor network of the multiple tensor networks, contract multiple nodes of the second tensor network in response to the ping request, to generate a probability distribution indicative of a state information of the second tensor network, transmit the probability distribution from the second tensor network to the first tensor network, and update the first tensor network to connect the probability distribution with at least one of multiple nodes of the first tensor network.
H04L 41/08 - Configuration management of networks or network elements
H04L 43/10 - Active monitoring, e.g. heartbeat, ping or trace-route
H04L 67/12 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks
G06N 3/042 - Knowledge-based neural networksLogical representations of neural networks
45.
PHOTOELECTROCHEMICAL WATER SPLITTING WITH CONCENTRATED SOLAR LIGHT
A method of fabricating an electrode device includes providing a substrate of the electrode device, the substrate having a surface, growing an array of conductive projections on the surface of the substrate such that each conductive projection of the array of conductive projections extends outward from the surface of the substrate, each conductive projection of the array of conductive projections including a nitride material, depositing a plurality of metal catalyst nanoparticles across the array of conductive projections, and implementing a surface treatment procedure to modify the plurality of metal catalyst nanoparticles. Implementing the surface treatment procedure includes removing a subset of the plurality of metal catalyst nanoparticles, and further depositing a further plurality of metal catalyst nanoparticles after removing the subset. The removed subset includes metal catalyst nanoparticles of the plurality of metal catalyst nanoparticles that are not lattice-matched with the nitride material.
C25B 11/02 - ElectrodesManufacture thereof not otherwise provided for characterised by shape or form
C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
C25B 9/50 - Cells or assemblies of cells comprising photoelectrodesAssemblies of constructional parts thereof
H10D 62/10 - Shapes, relative sizes or dispositions of the regions of the semiconductor bodiesShapes of the semiconductor bodies
H10F 77/14 - Shape of semiconductor bodiesShapes, relative sizes or dispositions of semiconductor regions within semiconductor bodies
46.
DETERMINING RISK OF FIBROMUSCULAR DYSPLASIA AND SYSTEMS AND METHODS OF USE THEREOF
Provided herein are systems and methods for determining a subject's risk of fibromuscular dysplasia (FMD) and/or abdominal aortic aneurysm (AAA), and methods of treatment and symptom management based thereon.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
47.
NOVEL CDK12/13 COVALENT INHIBITOR HAVING A FUSED RING STRUCTURE SUBSTITUENT OR PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (China)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Ding, Ke
Zhou, Licheng
Chinnaiyan, Arul M
Zhou, Kaijie
Yang, Jianzhang
Fan, Bohai
Chang, Yu
Wang, Zhen
Huang, Weixue
Wang, Xiaoju
Tien, Ching Yi
Abstract
The present invention relates to a preparation method for a novel CDK12/13 covalent inhibitor having a fused ring structure substituent or a pharmaceutical composition thereof and the use thereof. The novel CDK12/13 covalent inhibitor having a fused ring structure substituent has a structure shown as formula (I), and the compound can be used as a protein kinase inhibitor, can effectively and highly selectively inhibit the activity of CDK12/13 protein kinase, and can inhibit the proliferation, migration and invasion of a plurality of tumor cells.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
The performance of modern recommendation models is limited because of the memory bandwidth-hungry embedding layer reductions. A novel hybrid memory system is presented with DRAM and RRAM with PIM capability. The performance of traditional RRAM PIM is limited by the latency of bit-serial computation. The hybrid memory system presents a comprehensive optimization approach that includes access-pattern aware mapping, compute complexity reduction, and selective PIM reduction to offset this computation latency. An evaluation shows that the hybrid memory system offers significant performance, energy, and EDP improvement of 2.6×, 1.7×, and 4.4×, on average, compared to a CPU baseline.
The disclosure is directed to heterodimeric peptide reagents that specifically bind epidermal growth factor receptor (EGFR) and epidermal receptor growth factor 2 (ErbB2), as well as methods for detecting, targeting, diagnosing and/or treating diseases of the esophagus, including esophageal carcinoma, esophageal adenocarcinoma (EAC), high grade dysplasia (HGD) of the esophagus, and Barrett's neoplasia in a patient using the heterodimeric peptide reagents.
The present disclosure pertains to two-photon microscopy, and specifically to methods and systems for optimizing the performance of entangled two-photon absorption (ETPA) microscopy. An ETPA microscope is described with time delay tunability to optimize the coincidence of entangled photons on a sample. The optimization allows for increased two-photon absorption by the sample, resulting in increased luminescence of the sample. The ETPA microscopy systems and methods described allow for nonlinear imaging using excitation energy intensities six orders of magnitude lower than comparable two-photon absorption microscopy techniques using classical light.
A balloon occlusive aortic cannula having a hollow cannula and an inflation lumen having a distal end and an expandable element surrounding the hollow cannul and having an exterior surface. The expandable element is disposed on the distal end of the inflation lumen. The expandable element having a micro surface texture formed on the exterior surface. The micro surface texture having a plurality of surface features configured to engage an aortic wall and form a fluidic seal therebetween during a cardiopulmonary bypass procedure.
Provided herein are methods, compositions, kits and systems for analysis of the events and constituents of early embryogenesis. In particular, provided herein are reagents and methodologies for generation and use of peri-gastrulation trilaminar embryonic disc (PTED) embryoids.
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (HDAC6) inhibitors, and their use as therapeutics for the treatment of metabolic disorders (e.g., obesity, Diabetes), neurological disorders (e.g., Alzheimer's disease, Parkinson disease, Huntington disease), cancer (e.g., multiple myeloma, biliary tract cancer, non-small cell lung cancer, chronic lymphocytic leukemia) and other conditions related to HDAC6 activity (e.g., Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT)).
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Systems and methods for classifying encrypted data using an encrypted machine learning model are disclosed. An example method includes receiving, at one or more processors, encrypted data from a user that is encrypted in accordance with a first fully homomorphic encryption technique. The example method further includes analyzing, by the one or more processors executing an encrypted ML model that is encrypted in accordance with a second fully homomorphic encryption technique, the encrypted data to output an encrypted classification without decrypting the encrypted data. The example method further includes transmitting, by the one or more processors, the encrypted classification to a user computing device for decryption.
Methods and systems to identify actual esophageal tissue changes (e.g., during cardiac ablation) are disclosed. An example system includes a probe and a data analysis unit. The probe is configured for positioning in a patient's esophagus and includes a sheath, and a plurality of tendrils extendible by a user from an end of the sheath within the esophagus. Each tendril has a plurality of nodes spaced apart along the tendril, wherein each node of the plurality of nodes is configured to be used to introduce signals into esophageal tissue and/or receive signals affected by esophageal tissue. The data analysis unit is configured to determine a value of a characteristic indicative of actual change to esophageal tissue between two nodes based on a signal received using at least one of the nodes, and to provide an indication of actual esophageal tissue change based on the determined value.
A metal alloy is produced by flowing an electric current through a molten mixture before the mixture solidifies. The flow of electric current has a maximum power density of less than 1 W/cm2, less than 0.1 W/cm2, or even less than 0.01 W/cm2 and results in a refined microstructure having average features sizes less than those of the same alloy when conventionally produced in the absence of electric current. Application of the electric current at these exceptionally low power densities can be timed to ensure that the electric current is present at the beginning of and/or during the nucleation stage of alloy phase growth, which can maximize the refining effects of the electric current and/or minimize the duration of the electric current. The molten mixture can be formed in an electrode-equipped container, as a weld pool when welding metal materials together, or by remelting an already formed metal alloy.
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (USA)
Inventor
Bart-Smith, Hilary
Loth, Eric
Zhu, Joseph Jianzhong
Moored, Keith W.
Mivehchi, Amin
Zuo, Lei
Bacelli, Giorgio
Keow, Alicia
Abstract
The present invention relates to a renewable energy system designed to harness hydrokinetic energy from riverine environments using bio-inspired hydrofoil mechanisms. The system comprises a pair of hydrofoils configured to oscillate out-of-phase in response to water flow, a mechanical motion rectifier to convert oscillatory motion into unidirectional rotary motion, and a generator to produce electrical energy. A support structure stabilizes the components, while a control system optimizes energy generation by adjusting hydrofoil pitch angles and oscillation parameters based on sensory feedback. This innovative approach offers a scalable, efficient, and environmentally friendly solution for riverine hydrokinetics, minimizing ecological impact and adapting to varying site conditions.
The present disclosure provides JAK inhibitor analogs, and compositions and methods thereof for treating diseases or disorders (e.g., inflammatory bowel disease and ulcerative colitis).
A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A histotripsy therapy system configured for the treatment of brain tissue is provided, which may include any number of features. In one embodiment, the system includes an ultrasound therapy transducer, a drainage catheter, and a plurality of piezoelectric sensors disposed in the drainage catheter. The ultrasound therapy is configured to transmit ultrasound pulses into the brain to generate cavitation that liquefies a target tissue in the brain. The drainage catheter is configured to detect the ultrasound pulses. An aberration correction algorithm can be executed by the system based on the ultrasound pulses measured by the drainage catheter to automatically correct for an aberration effect caused by the ultrasound pulses passing through a skullcap of the patient.
In Multi-Policy Decision-Making (MPDM), many computationally-expensive forward simulations are performed in order to predict the performance of a set of candidate policies. In risk-aware formulations of MPDM, only the worst outcomes affect the decision making process, and efficiently finding these influential outcomes becomes the core challenge. Recently, stochastic gradient optimization algorithms, using a heuristic function, were shown to be significantly superior to random sampling. In this disclosure, it was shown that accurate gradients can be computed-even through a complex forward simulation-using approaches similar to those in dep networks. The proposed approach finds influential outcomes more reliably, and is faster than earlier methods, allowing one to evaluate more policies while simultaneously eliminating the need to design an easily-differentiable heuristic function.
G06N 3/008 - Artificial life, i.e. computing arrangements simulating life based on physical entities controlled by simulated intelligence so as to replicate intelligent life forms, e.g. based on robots replicating pets or humans in their appearance or behaviour
G06N 3/084 - Backpropagation, e.g. using gradient descent
G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks
H04N 1/00 - Scanning, transmission or reproduction of documents or the like, e.g. facsimile transmissionDetails thereof
The disclosure provides methods and compositions for treating cancer, e.g., lung cancer including NSCLC that are ALK positive. The compositions for treating ALK positive cancers comprise a polynucleotide construct comprising a polynucleotide sequence encoding a tumor suppressor candidate 2 (TUSC2) polypeptide.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
62.
MEDICAL DEVICE FOR GUIDEWIRE PLACEMENT AND RELATED METHOD
A medical device includes a needle coupled with a syringe and is configured to feed a guidewire through the needle and out of a tip of the needle with only one hand and without decoupling the needle from the syringe. A user can feed the guidewire through the device using the same hand holding the device and using the same hand that applies a vacuum in the syringe. The device frees up the user's other hand to control the position of an ultrasonic transducer to continuously visualize all steps of vascular access, including feeding of the guidewire into the blood vessel or other hollow cavity of a patient.
Methods and systems are disclosed to automatically reclassify households into a plurality of behavioral reference groups based on changing household energy usage data, and dynamically recluster the households into new behavioral reference groups when conditions are met. Once the households have been classified to appropriate behavioral reference groups, personalized, normative, energy use feedback messages are generated for the households of each behavioral reference group. An effectiveness of the customized messages at reducing household energy consumption may be monitored, and the customized messages may be adjusted over time to maximize the reductions in household energy consumption.
A method for detecting plant evapotranspiration includes: detecting, by an evapotranspiration (ET) sensor arranged in a canopy of a plant, a speed of air flowing through the canopy of plant, a temperature of the air and a relative humidity of the air over a plurality of time intervals; calculating, by a processor, an estimated mass the air using at least one of a convective mass transfer (CMT) model, a mass balance (MB) model, or an empirical (EM) model; determining, by the processor, a plant scaling coefficient; integrating, by the processor, the estimated mass flux of the air over the plurality of time intervals to obtain a running sum; and multiplying, by the processor, the running sum by the plant scaling coefficient to determine an estimated evapotranspiration of the plant.
Provided herein are methods, compositions, kits and systems for regulation of peptide function. In particular, provided herein are methods, compositions, kits and systems comprising nucleic acid constructs and fusion proteins comprising chemically-activated protein domains (CAPs) that regulate the activity of a fused peptide in the presence of a ligand.
A method is presented for identifying a cell type of a subject using laser emissions. The method includes: directing, by a light source, a light beam towards a biological sample, where the biological sample is disposed in a laser cavity; capturing, by a detector, spatial distribution of laser emissions from the biological sample; and identifying a cell type for the biological sample from the captured spatial distribution of laser emissions using machine learning.
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
G01N 15/0205 - Investigating particle size or size distribution by optical means
G01N 21/39 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using tunable lasers
G01N 33/483 - Physical analysis of biological material
A bowel gripping and distraction device includes a first bowel gripping feature configured to be inflatable to engage a bowel, the first gripping feature including a plurality of radially extending fins. A second bowel gripping feature is configured to be inflatable to engage the bowel, the first gripping feature including a plurality of radially extending fins. An elongation system is operable to extend a relative distance between the first bowel gripping feature and the second bowel gripping feature to apply a tensile force to the bowel of a patient, the tensile force being configured to encourage growth of the bowel through mechanotransductive treatment.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
68.
COMPOSITIONS AND METHODS FOR THE DETECTION OF HPV BIOMARKERS IN URINE
The present disclosure provides compositions, methods, and kits related to detecting and measuring human papillomavirus (HPV) (e.g., viral nucleic acid, cell-free tumor-derived DNA (ctDNA), trans-renal cell-free tumor DNA (TR-ctDNA), etc.) associated with an HPV infection or with an HPV-associated cancer. In particular, the present disclosure provides novel compositions, methods, and kits for diagnosing, treating and/or preventing human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) or other HPV-associated cancers.
Smart materials that can self-activate based on the material interface, generating a mismatch in the thermal and mechanical characteristics in response to variable environmental energy levels, allow for the development of intelligent and sustainable devices and systems. However, due to symmetric strain coupled with intrinsic isotropic heat transport at the material interface, their capacity to self-activate is fundamentally constrained, resulting in a restricted physical and sensory range as well as low mechanical durability. Unlike current 3-D materials frequently used in self-activation, 2-D materials offer a new way for in-plane thermal expansion without suffering from interfacial slip or structural deformation. This disclosure reports an anisotropic van der Waals thermal transfer and asymmetric expansion at a material interface enabling significantly enhanced self-actuation by interfacial a molybdenum disulfide (MoS2) layer (IML) within a metal-elastic structure.
This disclosure relates to compounds having a structure of Formula (I): that act as degraders of CBP/p300, pharmaceutical formulations thereof, and methods of using the compounds to treat diseases and disorders, such as cancer and cancer-related diseases and disorders.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
71.
BIOFILM-TARGETING NANOPARTICLES TO INCREASE THE ANTICARIES EFFECT OF FLUORIDE
Nanoparticles for treating a tooth in an oral cavity of a subject are provided. The nanoparticle comprises a biocompatible and biodegradable hydrophilic polymer, a matrix-degrading enzyme, and an anticaries active ingredient present in the nanoparticle at greater than or equal to about 20% by weight. The nanoparticle has a zeta potential between about −10 mV to about +10 mV at a pH of 7. The nanoparticle is capable of selectively accumulating within a biofilm matrix associated with a surface of the tooth in the oral cavity of the subject. Oral care composition and methods of treating a tooth in an oral cavity of a subject with such nanoparticles are also provided.
A monolithic gas chromatograph is presented. The monolithic gas chromatograph includes a separation column and a gas detector. The separation column has an inlet to receive a gas sample therein. The separation column resides in a first layer of an integrated chip. The gas detector has an ionization chamber and an ionization source. The ionization chamber has an inlet in fluid communication with an outlet of the separation column to receive a gas sample from the separation column. The ionization source is configured to ionize molecules of the gas sample residing in the ionization chamber. The gas detector resides in a second layer of the integrated chip. The monolithic gas chromatograph further includes a third layer disposed between the first layer and the second layer. The third layer is configured to electrically isolate the first layer from the second layer. The gas detector is fluidly coupled to the separation column.
A bowel gripping and distraction device includes a first bowel gripping feature configured to be inflatable to engage a bowel, the first gripping feature including a plurality of radially extending fins. A second bowel gripping feature is configured to be inflatable to engage the bowel, the first gripping feature including a plurality of radially extending fins. An elongation system is operable to extend a relative distance between the first bowel gripping feature and the second bowel gripping feature to apply a tensile force to the bowel of a patient, the tensile force being configured to encourage growth of the bowel through mechanotransductive treatment.
An example nasal airway tube includes a tubular body having a distal end and a proximal end. A surface at the distal end including an opening. The tubular body having an overall curvature with a radius of curvature defined relative to a longitudinal axis of the tube. An X-axis is defined by the longitudinal axis of the tube, and a Y-axis extends perpendicularly from the longitudinal axis and has a positive direction defined outwardly relative to the radius of curvature. At least a portion of the opening faces outwardly relative to the radius of curvature. A vector normal to a plane defined by the opening includes a positive Y-coordinate.
A system and process for CO2 capture and release can include an electrochemical de-acidification of a pH varying electrolyte cause by reduction of PCET active molecules in a flow cells to produce a pH varying electrolyte capable of CO2, followed by acidification of the pH varying electrolyte caused by oxidation of the PCET active molecules to release the captured CO2.
Techniques are presented for fabricating optoelectronic devices with integrated air bridges for improved efficiency. The optoelectronic device includes: a reflector disposed on the substrate; a spacer layer disposed on the reflector; and a thermophotovoltaic cell disposed on to the spacer layer, such that the spacer layer is arranged between the reflector and the thermophotovoltaic cell and the spacer layer includes a cavity which extends between the reflector and the thermophotovoltaic cell. Of note, the thermophotovoltaic cell is comprised of silicon material with one or more lateral p-n junctions formed therein.
In an example method for detecting indole, an indole producing bacterium, or an indole producing chemical, a polymeric detection tool is exposed to a sample and the polymeric detection tool is monitored for a red color change. The polymeric detection tool includes an acidic and oxygen soluble polymer and a nitrosation agent impregnated in walls of the acidic and oxygen soluble polymer. This example method can be used for detecting an indole producing bacterium in a body fluid sample.
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
G01N 21/29 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using visual detection
Currently, objection detection models require a large amount of training cycles on even the most powerful hardware, fundamentally limiting exploration of the model design space. This work proposes interchanging the constituent components of objection detection models without retraining to quickly build and evaluate new model designs. A typical objection detection model consists of multiple constituent components (submodels) and the conventional wisdom is to train all sub-models jointly. To alleviate this, a thin adapter is introduced that enables the recomposition of pre-trained sub-models without retraining them. In this way, a suite of new objection detection models are built with distinct accuracy and compute profiles at minimal training cost. These new models outperform by up to 3% in mAP on the COCO dataset at up to 99% less training cost when compared to conventional training approaches.
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
79.
INTELLIGENT SCAN SEQUENCE OPTIMIZATION FOR POWDER BED FUSION ADDITIVE MANUFACTURING USING LINEAR SYSTEMS THEORY
An approach for intelligent online scan sequence optimization to achieve uniform temperature distribution in LPBF using a control theoretic approach. The thermal dynamics of the LPBF process is modeled using the finite difference method and the next best feature (for example, stripe or island) that minimizes a thermal uniformity metric is found using a control theoretic approach. In simulations, the present approach yields up to 8.4 times improvement in thermal uniformity compared to existing heuristic approaches.
The present disclosure provides methods, devices, and kits useful for screening or characterizing extracellular vesicles (e.g., exosomes) by monitoring cell-type specific extracellular vesicle uptake and/or cells' feedback responses.
System and methods for determining pupil morphology during an ophthalmic surgical procedure. The system may receive surgical video data of an ophthalmic surgical procedure. The surgical video data may include images of at least a portion of an eye. The system may provide the surgical video data to an adaptive wavelet tensor feature extraction machine learning (ML) model to generate preprocessed image data, including preprocessed images with extracted features associated with anatomical components of the eye. The system may provide the preprocessed image data to an anatomy segmentation ML model to generate segmented image data and segmentation masks. The system may provide the segmented image data and segmentations masks to an obstruction classifier ML model to determine a size of a pupil of the eye in the segmented images. The system may generate a notification based upon the size of the pupil, and provide the notification to a user device.
G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
G06T 7/64 - Analysis of geometric attributes of convexity or concavity
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present disclosure provides compounds represented by Formula (IX): and the pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R4, R5, and X are as defined in the specification. Compounds having Formula (I) are adenosine deaminase acting on RNA 1 (ADAR1) inhibitors useful for the treatment of cancer and other diseases. Compounds having Formula (I) can be administered to a subject as a single agent or in combination with immune checkpoint inhibitors.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 215/44 - Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 215/42 - Nitrogen atoms attached in position 4
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
83.
HETEROSTRUCTURES WITH NANOSTRUCTURES OF LAYERED MATERIAL
A method of fabricating a heterostructure includes forming a layered material structure such that the layered material structure has an edge, and growing epitaxially a nanostructure of layered material laterally from the edge of the layered material structure such that an inplane interface between the layered material structure and the nanostructure is defined. Growing the nanostructure is implemented at a growth temperature sufficiently near a decomposition temperature of the layered material such that a nucleation interface of the nanostructure has a single atomic configuration.
H10D 30/47 - FETs having zero-dimensional [0D], one-dimensional [1D] or two-dimensional [2D] charge carrier gas channels having 2D charge carrier gas channels, e.g. nanoribbon FETs or high electron mobility transistors [HEMT]
The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting vascularized human intestinal organoid tissue having an intestine-specific EC transcriptional signature from hindgut spheroid tissue produced in vitro from the described methods.
An excitonic device includes a substrate and nanowires coupled to the substrate. Electrons and holes are spatially confined within an active region of each nanowire. The nanowires are operable for electroluminescent emission originating from excitons comprising bound states of electrons and holes in the active region of each nanowire.
H10H 20/812 - Bodies having quantum effect structures or superlattices, e.g. tunnel junctions within the light-emitting regions, e.g. having quantum confinement structures
H10H 20/819 - Bodies characterised by their shape, e.g. curved or truncated substrates
H10H 20/825 - Materials of the light-emitting regions comprising only Group III-V materials, e.g. GaP containing nitrogen, e.g. GaN
A device includes a substrate, a buffer layer supported by the substrate, and a plurality of nanostructures supported by the substrate. Each nanostructure of the plurality of nanostructures is shaped as a wall extending outward from the substrate. The walls of the plurality of nanostructures are interconnected to define a set of voids, each void of the set of voids extending outward from the substrate. The buffer layer is disposed between the substrate and each nanostructure of the plurality of nanostructures
Retention time drift caused by fluctuations in physical factors such as temperature ramping rate and carrier gas flow rate is ubiquitous in chromatographic measurements. Proper peak identification and alignment across different chromatograms is critical prior to any subsequent analysis. This work introduces a peak identification method called retention time trajectory (RTT) matching, which uses chromatographic retention times as the only input and identifies peaks associated with any subset of a predefined set of target compounds. RTT matching is also capable of reporting interferents. An RTT is a 2-dimensional (2D) curve formed uniquely by the retention times of the chromatographic peaks. The RTTs obtained from the chromatogram of a test sample and of pre-characterized library are matched and statistically compared. The best matched pair implies identification. Unlike most existing peak alignment methods, no mathematical warping or transformations are involved.
A system for mitigating backsputter to a thruster in a propulsion test facility includes a plate disposed in an output plume of the thruster and a magnetic field generator disposed about or at the plate and configured to generate a magnetic field between the thruster and the plate. The magnetic field generator is oriented such that a magnetic field is generated transverse to the output plume.
Methods of making optic structures (e.g., microring resonator, meta-elements) include imprinting a first surface of a moldable polymer having at least one inverse micro/nano-feature into a second surface of a first polymeric cladding layer disposed on a second substrate to form at least one trench micro/nano-feature contrapositive to the at least one inverse micro/nano-feature. A liquid polymeric precursor is applied into the at least one trench micro/nano-feature where it is solidified to form a solid polymer. A difference between a first refractive index of the first cladding layer and a second refractive index of the solid polymer is ≥about 0.05. The solid is heated for thermal reflow to define a meniscus followed by applying a second polymeric cladding layer thereon. Organic cladded (e.g., microring resonator) optic structures are also provided, which may have a quality (Q)-factor of ≥about 5×105 around 770 nm wavelength).
G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
G02B 6/136 - Integrated optical circuits characterised by the manufacturing method by etching
90.
Real-Time Protection For Mobile Devices From Shoulder
People use mobile devices ubiquitously for computing, communication, storage, web browsing, and more. Shoulder surfing occurs when a person near a mobile user peeks at the user's mobile device, potentially acquiring passcodes, PINs, browsing behavior, or other personal information. A technique is presented to protect information on a mobile device from shoulder surfing. The technique is designed to protect all types of on-screen information in real time, without any serious impediment to users' interactions with their mobile devices. In particular, images are generated that appear readable at close distances, but appear blurry or pixelated at farther distances and wider angles. This approach is capable of protecting on-screen information from shoulder surfers, operating in real time, and being minimally intrusive to the intended users.
This disclosure provides compositions and methods for stimulating the innate immune response in a subject with agents capable of stimulating an innate immune response in a subject upon administration to the subject (e.g., damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)). In particular, the present invention is directed to compositions of DAMPs/PAMPs and metals ions, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
Oncopia Therapeutics, Inc. d/b/a SK Life Science Labs (USA)
Inventor
Chen, Zhixiang
Rej, Rohan
Zhang, Xuqing
Bai, Longchuan
Kirchhoff, Paul
Wang, Shaomeng
Abstract
Described herein are compounds of Formulae I′ and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
93.
COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING SKIN DAMAGE
Provided herein are compositions and method for treating and preventing skin damage. In particular, provided herein are compositions that reverse, prevent and/or slow age-related skin damage.
Oncopia Therapeutics, Inc. d/b/a SK Life Science Labs (USA)
Inventor
Zhou, Haibin
Wu, Dimin
Wang, Changwei
Wang, Mi
Wang, Shaomeng
Rej, Rohan
Chen, Zhixiang
Acharyya, Ranjan Kumar
Bai, Longchuan
Kirchhoff, Paul
Xu, Guozhang
Zhang, Xuqing
Li, Zhenwu
Hu, Biao
Lu, Jianfeng
Abstract
Described herein are compounds or conjugates of Formula II and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Simon Fraser University Technology Licensing Office (Canada)
Inventor
Mozafari, Barzan
Wang, Xinyu
Dong, Rui
Liu, Jie
Zhao, Pinhan
Zhu, Yuxuan
He, Yang
Wang, Yuepeng
Abstract
Methods and systems for performing a query search to rewrite queries are provided. The method may comprise: receiving an input database query to perform a first database operation, wherein the first database operation occurs within a first period of time; analyzing the input database query to determine a set of one or more query segments of the input database query representative of the first database operation; generating a plurality of candidate output database queries based at least on the one or more query segments; and determining at least one confirmed output database query of the plurality of candidate output database queries, wherein the at least one confirmed output database query, when implemented by a computing device, causes the computing device to perform a second database operation equivalent to the first database operation within a second period of time shorter than or equal to the first period of time.
Disclosed herein are radiolabeled compounds that can act as antagonists of the μ-opioid receptor, including methods of making and using the same. The selective mu opioid receptor antagonists disclosed herein can improve safety for subjects as well as enable studies of the μ-opioid receptor using agonist/antagonist radioligand pairs.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
97.
IMAGE CLASSIFICATION OF COMMUNICATION CHANNEL FOR IDENTIFYINGSENDER
An electronic control unit (ECU) authentication system and method of determining an identity of a sender of a message, where the ECU authentication system is configured to perform the method. The method includes: obtaining distortion data of a data transmission signal sent by a sender over a physical channel through sampling the data transmission signal, wherein the distortion data represents extracted attributes of the data transmission signal as observed over the physical channel; generating distortion image data that represents the distortion data as an image; and identifying a sender of the data transmission signal based on an output generated by a classifier that takes the distortion image data as input.
Toyota Motor Engineering & Manufacturing North America, Inc. (USA)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Zhou, Feng
Khan, Shahid Aziz
Wang, Mengqi
Abstract
An integrated power module is disclosed for use with an electric vehicle. The power module includes: a motor drive printed circuit board having a bare-die semiconductor device embedded therein; and an onboard charger printed circuit board having a planar transformer embedded therein and an electrical connector. The onboard charger printed circuit board is configured to operate in a charging mode to supply a first amount of electricity to a battery of the electric vehicle. The electrical connector is configured to supply the first amount of electricity from an external electricity source and to the planar transformer.
A device includes a substrate, a ferroelectric structure supported by the substrate, the ferroelectric structure having a wurtzite crystal structure, a switchable conduction path in the ferroelectric structure, the switchable conduction path being disposed along a lateral domain all in the ferroelectric structure, the lateral domain wall defining a first portion of the ferroelectric structure and a second portion of the ferroelectric structure having a first polarity and a second polarity, respectively, and an electrode disposed relative to the ferroelectric structure such that a voltage applied to the electrode establishes or removes the lateral domain wall and the switchable conduction path in the ferroelectric structure.
H10D 62/852 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group III-V materials, e.g. GaAs being Group III-V materials comprising three or more elements, e.g. AlGaN or InAsSbP
G11C 11/22 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using electric elements using ferroelectric elements
100.
IMAGE CLASSIFICATION OF COMMUNICATION CHANNEL FOR IDENTIFYING SENDER
An electronic control unit (ECU) authentication system and method of determining an identity of a sender of a message, where the ECU authentication system is configured to perform the method. The method includes: obtaining distortion data of a data transmission signal sent by a sender over a physical channel through sampling the data transmission signal, wherein the distortion data represents extracted attributes of the data transmission signal as observed over the physical channel; generating distortion image data that represents the distortion data as an image; and identifying a sender of the data transmission signal based on an output generated by a classifier that takes the distortion image data as input.
H04W 4/48 - Services specially adapted for particular environments, situations or purposes for vehicles, e.g. vehicle-to-pedestrians [V2P] for in-vehicle communication
B60W 60/00 - Drive control systems specially adapted for autonomous road vehicles
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
